- Chief Executive Officer
- DisperSol Technologies
Edward M. Rudnic, Ph.D., is a pharmaceutical executive and entrepreneur with an extensive background in the biopharmaceutical industry. He has served in leading capacities as the head of several start-ups, public companies, and venture-related funds/companies.
Dr. Rudnic was founder, chairman and CEO of MiddleBrook Pharmaceuticals (Nasdaq: MBRK, previously Advancis; Nasdaq: AVNC), where he lead the development of an FDA approved anti-infective product. Prior to founding MiddleBrook, he was Senior Vice President, Development and Technical Operations for Shire Laboratories, where he was the lead inventor of Carbatrol/Equetro with cumulative sales of over $1 billion to date, and co-inventor of Adderall XR with cumulative sales of over $10 billion to date. Most recently, he served as the Chief Operating Officer of QRx Pharma, after the company filed its NDA for Moxduo. Following FDA’s rejection of the NDA, he served as Chief Executive Officer during the company’s wind-down.
Previously, he was in management roles at Merck (Schering-Plough) and at Bristol Myers-Squibb (E.R. Squibb). He has been named lead inventor or co-inventor of 54 issued U.S. patents, and numerous related international patents, in such areas of novel drug delivery systems, solid dosage form research, process development and polymer/material science. Dr Rudnic has acted in numerous consulting capacities to the pharmaceutical industry.
Dr. Rudnic serves as an adjunct associate professor for the University of Maryland Department of Pharmaceutical Sciences, and an adjunct professor at the University of Rhode Island Department of Pharmaceutical Sciences. He served as Vice Chairman, Biotechnology, and Chairman of the Technology Council of Maryland. He has been appointed by Governors Ehrlich and O’Malley to several state boards and commissions. Dr. Rudnic holds a B.S. in Pharmacy, a M.S. in Pharmaceutics, and a Ph.D. in Pharmaceutical Sciences from the University of Rhode Island.